ARAY (Accuray) Moat Score: 5/10 (As of Jun. 29, 2026)


ARAY Accuray Inc ARAY
44 GF Score
Price $0.26
GF Value $1.34
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Accuray Moat Score?

Accuray ARAY -16.53% 44 Moat Score is 5 as of Jun. 29, 2026. GuruFocus rates ARAY with a GF Score™ of 44/100 and a GF Value™ of $1.34 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Accuray ranks better than 91.25% on this metric.

Accuray has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Accuray has Narrow Moat: Accuray Inc has a solid narrow moat due to its valuable intellectual property in medical devices and some customer loyalty. However, the company faces strong competition and limited pricing power, which prevents it from achieving a wide moat status.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Accuray might have Narrow Moat - Solid narrow moat.

Accuray  (NAS:ARAY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Accuray Moat Score Related Terms

ARAY vs PETV, NSPR, RDGL: Moat Score Comparison

For the Medical Devices subindustry, Accuray's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accuray Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accuray's Moat Score distribution charts can be found below:

* The bar in red indicates where Accuray's Moat Score falls into.


ARAY
44GF Score
Accuray Inc ARAY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Accuray (ARAY) has a Moat Score of 5 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Accuray ranks #74 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is Accuray's Moat Score too high?
Accuray's current Moat Score is 5. Based on the distribution chart, Accuray ranks #74 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Accuray has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Accuray's Moat Score compare to PETV and NSPR?
According to the Medical Devices & Instruments industry distribution chart, Accuray ranks #74 out of 846 companies for Moat Score. This places Accuray in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Accuray's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accuray stock overvalued right now?
Based on GuruFocus' analysis, Accuray (ARAY) is currently considered Possible Value Trap. The stock's GF Value™ is $1.34, compared to a current price of $0.26 — trading 80.3% below its estimated fair value. The current Moat Score is 5. Accuray's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Accuray (ARAY), the current Moat Score is 5 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Accuray (ARAY) Overvalued in 2026?

Based on GuruFocus' analysis, Accuray stock appears to be undervalued. The current stock price of $0.26 is trading 80.3% below its estimated GF Value™ of $1.34. GuruFocus considers Accuray to be Possible Value Trap.

Key valuation signals for ARAY:

  • Moat Score: 5
  • GF Value™: $1.34 vs. price of $0.26 (80.3% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the ARAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Accuray Business Description

Other Exchanges 0H8I:UKXEJ:Germany
Address 1240 Deming Way, Madison, WI, USA, 53717
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
44GF Score

Get the complete analysis for ARAY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price
$1.34
GF Value